Letter by Zhao et al Regarding Article, “Biomarker-Based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation: A Registry-Based, Multicenter, Randomized, Controlled Study”

“We found no benefit of individually tailored, multidimensional treatment recommendations based on ABC-AF-stroke and ABC-AF-bleeding risk scores compared with usual guideline-based care”

“While novel biomarker-based risk scores have been validated in different populations, the clinical utility of risk scores to guide treatment decisions and improve clinical outcomes has rarely been prospectively evaluated. We performed a pragmatic registry-based trial to evaluate whether the tailoring of treatment recommendations based on patients’ ABC-AF risk scores improves clinical outcomes as compared with usual guideline-based care in patients with AF.”